Journals / Retina-Vitreus / 2015 / Cilt: 23 - Sayı: 2

Comparison of Pneumatic Displacement Method Anti VEGF and Tpa with Intravitreal Anti VEGF Therapy Alone in Fresh Limited Submacular Hemorrhage Cases

Taze Sınırlı Submaküler Hemoraji Olgularında Kombine Tpa, Anti VEGF ve Pnömatik Yer Değiştirme Yöntemi ile Tek Başına İntravitreal Anti VEGF Tedavisinin Karşılaştırılması

Pages
154–158
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

One patient had rhegmatogenous retinal detachment as a complication of pneumatic displacement.Conclusion: The treatment of submacular haemorrhage with intravitreal injection of tPA and antİ-VEGF and expansile gas is an encouraging procedure leading to improved visual acuity

📌 3 Key Takeaways

🎯
Objective & Hypothesis:To compare the results of intravitreal tissue plasminogen activator (tPA), anti-VEGF and expansile gas injection with intravitreal anti-VEGF therapy alone for limited submacular haemorrhage.Material and Methods: The medical records of patients who presented with submacular haemorrhage between January 2007 and January 2014 were reviewed.
📊
Key Findings & Data:Patients who had acute onset of bleeding (15 days), treated with intravitreal injection of tPA solution, anti-VEGF (50 ?g in 0.05 ml) and expansile gas (0.3-0.4 cc of 100% SF6), and followed up at least 6 months, involved in this study as group A.
💡
Conclusion & Impact:One patient had rhegmatogenous retinal detachment as a complication of pneumatic displacement.Conclusion: The treatment of submacular haemorrhage with intravitreal injection of tPA and antİ-VEGF and expansile gas is an encouraging procedure leading to improved visual acuity
🔬Design:Review & Systematic Survey
📍Scope:2007 Verileri
⚙️Variables:Domain Parameters

Abstract

To compare the results of intravitreal tissue plasminogen activator (tPA), anti-VEGF and expansile gas injection with intravitreal anti-VEGF therapy alone for limited submacular haemorrhage.Material and Methods: The medical records of patients who presented with submacular haemorrhage between January 2007 and January 2014 were reviewed. Patients who had acute onset of bleeding (15 days), treated with intravitreal injection of tPA solution, anti-VEGF (50 ?g in 0.05 ml) and expansile gas (0.3-0.4 cc of 100% SF6), and followed up at least 6 months, involved in this study as group A. And patients who had acute onset of bleeding (15 days), treated with intravitreal ranibizumab alone and followed up at least 6 months were involved in this study as group B. Mean best-corrected visual acuity (BCVA) post-treatment results and complications of two groups were compared.Results: A total of 10 eyes of 15 patients were involved in this study. 6 eyes were involved as group A and 4 eyes as group B. The mean duration of hemorrhage was 9.1±5.7 days in group A and 10±2.1 days in group B. The etiology of haemorrhage were age-related macular degeneration (ARMD) in 4 eyes (66.6%), in group A and ARMD in all eyes in group B. There was no statistically significant difference in preoperative mean BCVA between the two groups, however, BCVA results were significantly better in group A after treatment. One patient had rhegmatogenous retinal detachment as a complication of pneumatic displacement.Conclusion: The treatment of submacular haemorrhage with intravitreal injection of tPA and antİ-VEGF and expansile gas is an encouraging procedure leading to improved visual acuity

Özet

Sınırlı submakular hemoraji olgularında intravitreal doku plazminojen aktivatörü ve genleşebilen gaz enjeksiyonu sonuçlarının tek başına anti-VEGF enjeksiyonu ile karşılaştırılması. Gereç ve Yöntem: Ocak 2007 ve Ocak 2014 tarihleri arasında başvuran ve submakular hemoraji olarak değerlendirilen olguların medikal kayıtları retrospektif olarak incelendi. Akut başlangıçlı kanaması olan (15 gün), intravitreal doku plazminojen aktivatörü (tPA: 50 ?g/0.05 ml), anti-VEGF ve genleşebilen gaz enjeksiyonu (0.3 cc saf SF6) ile tedavi edilen ve en az 6 ay takibi olan hastalar grup A olarak tanımlandı. Akut başlangıçlı kanaması olan (15 gün), tek başına intravitreal anti-VEGF enjeksiyonu ile tedavi edilen ve en az 6 ay takibi olan hastalar grup B olarak tanımlandı. Her iki grupta en iyi düzeltilmiş görme keskinliği (EİDGK) sonuçları ve cerrahi komplikasyonlar açısından karşılaştırıldı.Bulgular: Submaküler hemoraji ile başvuran 15 hastadan 10'u çalışmaya dahil edildi. 6'sı grup A'i ve 4'ü grup B'yi oluşturdu. Hemoraji nedeni olarak, grup A da yer alan 6 hastadan 4'ünde (%66.6) YBMD, grup B de yer alan 4 hastada ise YBMD (%100) saptandı. İki grup arasında başlangıç EİDGK açısından fark saptanmazken sonuç EİDGK'nin grup A da anlamlı olarak daha yüksek olduğu saptandı (p<0.05). Pnömatik yer değiştirme prosedürü sonrası bir yırtıklı retina dekolmanı izlendiği görüldü.Sonuç: Bu çalışmada sınırlı submakuler hemoraji tedavisinde pnömatik yer değiştirme prosedürünün ümit verici bir yöntem gibi gözükmektedir. Sadece anti-VEGF uygulanan olgularda görme giderek azalırken, pnömatik yer değiştirme tPA ve anti-VEGF kombinasyonu yapılan hastaların çoğunluğunda görmede ciddi artışlar elde edilmiştir

🔖

Cite This Article

ÇUBUK, M. Ö., ÖZDEK, Ş., HASANREİSOĞLU, B. (2015). Comparison of Pneumatic Displacement Method Anti VEGF and Tpa with Intravitreal Anti VEGF Therapy Alone in Fresh Limited Submacular Hemorrhage Cases. Retina-Vitreus, Cilt: 23 - Sayı: 2, 154–158. https://ajindex.com/articles/307636

References (11)

  1. Chan WM, Liu DT, Lai TY, et al. Extensive submacular haemorrhage in polypoidal choroidal vasculopathy managed by sequential gas disp- lacement and photodynamic therapy: A pilot study of one-year follow up. Clin Experiment Ophthalmol 2005;33:611-8.
  2. Chen CY, Hooper C, Chiu D et al. Management of submacular hemorr- hage with intravitreal injection of tissue plasminogen activator and expansile gas. Retina 2007;27:321-8. 3. Hassan AS, Johnson MW, Schneiderman TE et al. Management of sub- macular hemorrhage with intravitreous tissue plasminogen activator injection and pneumatic displacement. Ophthalmology 1999;106:1900-7. Lewis H. Intraoperative fibrinolysis of submacular hemorrhage with tissue plasminogen activator and surgical drainage. Am J Ophthalmol 1994;118:559-68.
  3. Lim JI, Drews-Botsch C, Sternberg Jr P et al. Submacular hemorrhage removal. Ophthalmology 1995;102:1393-9.
  4. Cereda MG, Parolini B, Bellesini E et al. Surgery for CNV and auto- logous choroidal RPE patch transplantation: exposing the submacular space. Graefes Arch Clin Exp Ophthalmol. 2010;248:37-47.
  5. Ibanez HE, Williams DF, Thomas MA et al. Surgical management of submacular hemorrhage. A series of 47 consecutive cases. Arch Oph- thalmol 1995;113: 62-9.
  6. Arias L, Mones J. Transconjunctival sutureless vitrectomy with tissue plasminogen activator, gas and intravitreal bevacizumab in the mana- gement of predominantly hemorrhagic age-related macular degenera- tion. Clin Ophthalmol 2010; 4:67-72.
  7. Meyer CH, Scholl HP, Eter N et al. Combined treatment of acute sub- retinal haemorrhages with intravitreal recombined tissue plasmino- gen activator, expansile gas and bevacizumab: a retrospective pilot study. Acta Ophthalmol 2008; 86: 490-4.
  8. Matt G, Sacu S, Stifter E et al. Combination of Intravitreal rTPA, gas and ranibizumab for extensive subfoveal haemorrhages secondary to neovascular age-related macular degeneration. Klin Monbl Augenhe- ilkd 2010;227: 221-5.
  9. Sacu S, Stifter E, Vecsei-Marlovits PV et al. Management of extensive subfoveal haemorrhage secondary to neovascular agerelated macular degeneration. Eye (Lond) 2009;23: 1404-10.
  10. Treumer F, Roider J, Hillenkamp J. Longterm outcome of subretinal coapplication of rtPA and bevacizumab followed by repeated intravit- real anti-VEGF injections for neovascular AMD with submacular hae- morrhage. Br J Ophthalmol 2012;96:708-13.
  11. Benner JD, Hay A, Landers MB et al. Fibrinolytic-assisted removal of experimental subretinal hemorrhage within seven days reduces outer